NEW YORK, Dec. 12, 2019 /PRNewswire/ -- WeissLaw LLP is
investigating possible breaches of fiduciary duty and other
violations of law by the Board of Directors of Diplomat Pharmacy,
Inc. ("Diplomat" or the "Company") (NYSE: DPLO) in connection with
the proposed acquisition of the Company by UnitedHealth Group's
(NYSE: UNH) OptumRx. Under the terms of the acquisition
agreement, DPLO shareholders will receive $4 per share in cash.
If you own DPLO shares and wish to discuss
this investigation or have any questions concerning this notice or
your rights or interests, visit our website:
https://weisslawllp.com/diplomat-pharmacy-inc-investigation/
Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
WeissLaw is investigating whether Diplomat's Board acted to
maximize shareholder value prior to entering into the acquisition
agreement. Notably, the deal represents a 31% discount
from DPLO's closing price on Friday, the last day of trading before
the deal was announced. Additionally, the Company's "crown
jewel" infusion business, as one analyst put it, operates in all 50
states and Washington D.C.
Given these facts, WeissLaw is concerned whether the proposed
acquisition agreement undervalues the Company, whether the Board
ran a fair process, and whether all material information related to
the proposed acquisition is fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-diplomat-pharmacy-inc-300974265.html
SOURCE WeissLaw LLP